Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio

Beckman Coulter Life Sciences (Brea, CA, USA) highlighted its expanding portfolio of clinical flow cytometry solutions, including its latest innovations ranging from portfolio extensions to its range of single-color antibodies, high quality IVD panels and customized solutions, at the 70th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Laboratory Expo (CLE) in Chicago, USA.

Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Its latest innovations highlighted at AACC 2018 included ClearLLab Casebook 5C, a step by step illustrative resource into complex pattern recognition for leukemia and certain lymphomas, using the ClearLLab panel of reagents; enhanced portfolio of single color CE-IVD and analyte-specific reagents (ASR); DURA Innovations dry reagent technology, available in a range of services and reagents including ClearLLab; and the company’s expanded external business resources - the LUCID custom design and cocktailing services and RESOURCE contract manufacturing services, both of which are underpinned by DURA Innovations.


The ClearLLab5C Casebook provides the clinical history of 16 patients, illustrating the progressive analysis of flow cytometric immunophenotyping data by means of numerous color-coded illustrated scatter plots. These first assess and then assign the cells before giving a detailed characterization of the aberrant population according to the presence or absence of antigens. It includes patients with characteristic findings typical of various lymphoid and myeloid neoplasms as well as those with clinical and/or laboratory findings suggesting an underlying neoplastic process, but in which no immunophenotypic abnormality is identified. Specimen types include peripheral blood, bone marrow, and lymph nodes. Each case concludes with an assessment of the immunophenotypic findings as well as potential pitfalls.

“By standardizing the process, ClearLLab has removed one of the limitations to flow cytometry gaining its place in the routine lab, removing the need for a lab to manually prepare and design panels, a time- consuming process,” said Dr. Mario Koksch, Vice President and General Manager of Beckman Coulter’s Cytometry Business Unit.

At AACC 2018, Beckman Coulter also highlighted its largest portfolio of single color CE-IVD and ASR conjugated antibodies. The company manufactures all its single color reagents under Good Manufacturing Practices (GMP) in facilities that adhere to the highest standards in the industry. Their tandem dye stability and lot-to-lot consistency ensure reproducible and reliable results.

Also highlighted at the event was Beckman Coulter’s DURA Innovations dry, unitized reagent assays that help laboratories to simplify sample preparation, by reducing preparation time and reagent waste. The company’s panel design experts have created a range of multi-color pre-formulated options to standardize flow cytometry workflows, whether used for clinical research or research studies. The panels include single color compensation tubes for enhanced accuracy in off the shelf products and LUCID solutions. These solutions are at the heart of the company’s expanded external business resources, delivering off-the-shelf reagents, customized solutions through LUCID custom design and cocktailing services (CDS), or in bulk through RESOURCE contract manufacturing services (CMS).

“Dura Innovations solutions deliver greater efficiency while ensuring they have confidence in delivering high quality, reproducible results – and that that they will be compliant with current exacting standards,” said Dr. Koksch. “Through the technology of DURA Innovations, and the resources we provide, we are able to demonstrate that producing in-house cocktails is no longer the most efficient way to save time and costs. In contrast, we are able to offer customers choice and flexibility, tailoring a service exactly to their requirements, from small quantities to high volume throughput demands.”